1. Scrip

Sanwa and Kowa's DPP-4 licensing deal goes global

 
• By Ian Haydock

Sanwa Kagaku Kenkyushohas granted fellow Japanese firm [C#200200841:Kowa]exclusive development and marketing rights to its antidiabetic DPP-4 inhibitor, SK-0403, in all markets worldwide excluding South Korea, China and Taiwan. The agreement extends an August co-development and co-commercialisation alliance for Japan, where SK-0403 is in Phase II trials. Sanwa will receive undisclosed upfront, milestone and royalty payments. [C#200200841:Kowa] recently extended its US marketing capability through the acquisition of [C#200500155:ProEthic] Pharmaceuticals in August (Scrip Online, August 5th, 2008).

Sanwa Kagaku Kenkyushohas granted fellow Japanese firm Kowaexclusive development and marketing rights to its antidiabetic DPP-4 inhibitor, SK-0403, in all markets worldwide excluding South Korea, China and Taiwan. The agreement extends an August co-development and co-commercialisation alliance for Japan, where SK-0403 is in Phase II trials. Sanwa will receive undisclosed upfront, milestone and royalty payments. Kowa recently extended its US marketing capability through the acquisition of ProEthic Pharmaceuticals in August (Scrip Online, August 5th, 2008).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.